CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Northwest Biotherapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Northwest Biotherapeutics Inc
SUITE 800, 4800 MONTGOMERY LANE
Phone: (240) 497-9024p:240 497-9024 BETHESDA, MD  20814  United States Ticker: NWBONWBO
Business Summary
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairperson of the Board, President, Chief Executive Officer, Chief Financial Officer, Chief Accoun Linda F.Powers 67 6/8/2020 5/17/2007
Senior Vice President, General Counsel Leslie J.Goldman 77 6/8/2011 6/8/2011
Chief Scientific Officer, Corporate Secretary, Director Alton L.Boynton 78 1/1/2012 1/1/1998
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Flaskworks, LLC 38 Wareham Street Boston MA United States

Business Names
Business Name
Aracaris Capital, Ltd.
Flaskworks LLC
Flaskworks, LLC
4 additional Business Names available in full report.

General Information
Number of Employees: 25 (As of 12/31/2023)
Outstanding Shares: 1,189,970,308 (As of 2/28/2024)
Shareholders: 46,111
Stock Exchange: OTC
Federal Tax Id: 943306718
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024